1. Home
  2. MNKD
  3. MNKD News

Latest MannKind Corporation (MNKD) News on January 19, 2025

MannKind Expands Executive Leadership Team
MNKD

GlobeNewswire

12 days ago

MannKind Expands Executive Leadership Team

Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10
MNKD

Insider Monkey

12 days ago

Here’s Why MannKind Corporation (NASDAQ:MNKD) Is Among the Best Diabetes Stocks to Buy Under $10

Exploring 3 High Growth Tech Stocks In The United States
MNKD

Simply Wall St.

a month ago

Exploring 3 High Growth Tech Stocks In The United States

MNKD

MT Newswires

a month ago

MannKind Shares Rise After Wells Fargo Begins Coverage

MNKD

MT Newswires

a month ago

Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target

MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years
MNKD

Simply Wall St.

a month ago

MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years

MNKD

MT Newswires

a month ago

MannKind Shares Rise After Upgrade From RBC

MNKD

MT Newswires

a month ago

RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7

MNKD

MT Newswires

a month ago

MannKind Launches Exchange of Convertible Notes With Cash, Common Stock

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MNKD

GlobeNewswire

a month ago

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MNKD

MT Newswires

a month ago

MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MNKD

GlobeNewswire

a month ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

MNKD

MT Newswires

a month ago

MannKind, Cipla Say Afrezza Inhalation Powder Approved for Diabetes in India

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MNKD

GlobeNewswire

a month ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
MNKD

Simply Wall St.

2 months ago

MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

MNKD

Thomson Reuters StreetEvents

2 months ago

Q3 2024 MannKind Corp Earnings Call

MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
MNKD

GuruFocus.com

2 months ago

MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD

Motley Fool

2 months ago

MannKind (MNKD) Q3 2024 Earnings Call Transcript

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
MNKD

Zacks

2 months ago

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

MannKind (MNKD) Matches Q3 Earnings Estimates
MNKD

Zacks

2 months ago

MannKind (MNKD) Matches Q3 Earnings Estimates

MNKD

Associated Press Finance

2 months ago

MannKind: Q3 Earnings Snapshot

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
MNKD

GlobeNewswire

2 months ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For
MNKD

GuruFocus.com

2 months ago

MannKind Corp (MNKD) Q3 2024 Earnings Report Preview: What To Look For

MannKind to Present at 2024 UBS Healthcare Conference
MNKD

GlobeNewswire

2 months ago

MannKind to Present at 2024 UBS Healthcare Conference

High Growth Tech Stocks To Watch In November 2024
MNKD

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In November 2024

MNKD

MT Newswires

2 months ago

MannKind Says Phase 1 Trial of Nintedanib Dry Powder Inhaler Met Primary Objective

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MNKD

GlobeNewswire

2 months ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
MNKD

Zacks

3 months ago

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MNKD

GlobeNewswire

3 months ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD

GlobeNewswire

3 months ago

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...
MNKD

GuruFocus.com

3 months ago

MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
MNKD

Zacks

3 months ago

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Why MannKind (MNKD) Could Beat Earnings Estimates Again
MNKD

Zacks

3 months ago

Why MannKind (MNKD) Could Beat Earnings Estimates Again

Exploring High Growth Tech Stocks In The United States October 2024
MNKD

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks In The United States October 2024

MannKind (MNKD) Just Overtook the 20-Day Moving Average
MNKD

Zacks

3 months ago

MannKind (MNKD) Just Overtook the 20-Day Moving Average

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
MNKD

GlobeNewswire

4 months ago

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish
MNKD

Insider Monkey

4 months ago

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish

MNKD

MT Newswires

4 months ago

MannKind Receives Clearance in Japan for Phase 3 Trial of Clofazimine Inhalation Suspension

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD

GlobeNewswire

4 months ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Cancer Stock
MNKD

Insider Monkey

4 months ago

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish on This Cancer Stock

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
MNKD

GlobeNewswire

4 months ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 25,000 Shares of MannKind ...
MNKD

GuruFocus.com

4 months ago

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 25,000 Shares of MannKind ...

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 80,000 Shares of MannKind ...
MNKD

GuruFocus.com

5 months ago

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 80,000 Shares of MannKind ...

High Growth Tech Stocks To Watch In August 2024
MNKD

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In August 2024

MannKind to Present at Upcoming Conferences
MNKD

GlobeNewswire

5 months ago

MannKind to Present at Upcoming Conferences

Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
MNKD

GlobeNewswire

5 months ago

Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board

Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
MNKD

Zacks

5 months ago

Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?

MannKind (MNKD) Q2 2024 Earnings Call Transcript
MNKD

Motley Fool

5 months ago

MannKind (MNKD) Q2 2024 Earnings Call Transcript

MNKD

MT Newswires

5 months ago

MannKind's Shares Rise After Company Posts Higher Q2 Non-GAAP Net Income, Revenue

MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
MNKD

Zacks

5 months ago

MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
MNKD

Zacks

5 months ago

MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates

MNKD

Associated Press Finance

5 months ago

MannKind: Q2 Earnings Snapshot

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
MNKD

GlobeNewswire

5 months ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MNKD

GlobeNewswire

6 months ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
MNKD

GlobeNewswire

6 months ago

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
MNKD

Simply Wall St.

6 months ago

Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?

All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
MNKD

Zacks

6 months ago

All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
MNKD

Zacks

6 months ago

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?

MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
MNKD

Zacks

6 months ago

MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
MNKD

GlobeNewswire

7 months ago

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years
MNKD

Simply Wall St.

7 months ago

Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
MNKD

GlobeNewswire

7 months ago

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions

MNKD

MT Newswires

8 months ago

MannKind Agrees to Cross License Deal With Pulmatrix

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MNKD

PR Newswire

8 months ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MNKD

GlobeNewswire

8 months ago

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

MannKind (MNKD) Upgraded to Strong Buy: Here's Why
MNKD

Zacks

8 months ago

MannKind (MNKD) Upgraded to Strong Buy: Here's Why

MannKind First Quarter 2024 Earnings: Beats Expectations
MNKD

Simply Wall St.

8 months ago

MannKind First Quarter 2024 Earnings: Beats Expectations

MNKD

GuruFocus.com

8 months ago

MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript
MNKD

Insider Monkey

8 months ago

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript

Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why
MNKD

Simply Wall St.

8 months ago

Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why

MannKind (MNKD) Q1 2024 Earnings Call Transcript
MNKD

Motley Fool

8 months ago

MannKind (MNKD) Q1 2024 Earnings Call Transcript

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MNKD

Zacks

8 months ago

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MNKD

Zacks

8 months ago

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

MNKD

Associated Press Finance

8 months ago

MannKind: Q1 Earnings Snapshot

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MNKD

GlobeNewswire

8 months ago

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

MNKD

MT Newswires

8 months ago

MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD

GlobeNewswire

8 months ago

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
MNKD

GlobeNewswire

9 months ago

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
MNKD

GlobeNewswire

9 months ago

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MNKD

MT Newswires

9 months ago

MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD

GlobeNewswire

9 months ago

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Repays Certain Debt Obligations
MNKD

GlobeNewswire

10 months ago

MannKind Repays Certain Debt Obligations

MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
MNKD

Simply Wall St.

10 months ago

MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
MNKD

Zacks

10 months ago

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

MannKind Announces CFO Transition
MNKD

GlobeNewswire

10 months ago

MannKind Announces CFO Transition

Jim Cramer Says You Should Avoid These 11 Stocks
MNKD

Insider Monkey

10 months ago

Jim Cramer Says You Should Avoid These 11 Stocks

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
MNKD

GlobeNewswire

10 months ago

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
MNKD

GlobeNewswire

10 months ago

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

MannKind Corporation Announces Participation at Upcoming Conferences
MNKD

GlobeNewswire

10 months ago

MannKind Corporation Announces Participation at Upcoming Conferences

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts
MNKD

Simply Wall St.

a year ago

Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts

MannKind Full Year 2023 Earnings: Beats Expectations
MNKD

Simply Wall St.

a year ago

MannKind Full Year 2023 Earnings: Beats Expectations

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript
MNKD

Insider Monkey

a year ago

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript

MNKD

Thomson Reuters StreetEvents

a year ago

Q4 2023 MannKind Corp Earnings Call

MannKind (MNKD) Q4 2023 Earnings Call Transcript
MNKD

Motley Fool

a year ago

MannKind (MNKD) Q4 2023 Earnings Call Transcript

Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings
MNKD

Zacks

a year ago

Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
MNKD

Zacks

a year ago

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

MNKD

GuruFocus.com

a year ago

MannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
MNKD

GlobeNewswire

a year ago

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
MNKD

GlobeNewswire

a year ago

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
MNKD

GlobeNewswire

a year ago

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Share on Social Networks: